124 related articles for article (PubMed ID: 17804466)
21. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
[TBL] [Abstract][Full Text] [Related]
22. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.
Falvella FS; Cremolini C; Miceli R; Nichetti F; Cheli S; Antoniotti C; Infante G; Martinetti A; Marmorino F; Sottotetti E; Berenato R; Caporale M; Colombo A; de Braud F; Di Bartolomeo M; Clementi E; Loupakis F; Pietrantonio F
Pharmacogenomics J; 2017 Jul; 17(4):331-336. PubMed ID: 27001121
[TBL] [Abstract][Full Text] [Related]
23. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen Activation System in Rectal Adenocarcinoma.
Razik E; Kobierzycki C; Grzegrzolka J; Podhorska-Okolow M; Drag-Zalesinska M; Zabel M; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6009-15. PubMed ID: 26504024
[TBL] [Abstract][Full Text] [Related]
25. Antigen levels of the urokinase-type plasminogen activator and its gene polymorphisms in colorectal cancer.
Przybyłowska K; Smolarczyk K; Kulig A; Romanowicz-Makowska H; Dziki A; Ulańska J; Pander B; Błasiak J
Cancer Lett; 2002 Jul; 181(1):23-30. PubMed ID: 12430175
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
Espino A; Villagrán A; Vollrath V; Hanckes P; Salas R; Farah A; Solís N; Pizarro M; Escalona A; Boza C; Pérez G; Carrasco G; Padilla O; Miquel JF; Nervi F; Chavez-Tapia NC; Arab JP; Alvarez-Lobos M; Arrese M; Riquelme A
Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
[TBL] [Abstract][Full Text] [Related]
27. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
28. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
29. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
30. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
31. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1.
Sánchez-Tilló E; de Barrios O; Siles L; Amendola PG; Darling DS; Cuatrecasas M; Castells A; Postigo A
Clin Cancer Res; 2013 Mar; 19(5):1071-82. PubMed ID: 23340304
[TBL] [Abstract][Full Text] [Related]
32. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
33. Interleukin promoter polymorphisms and prognosis in colorectal cancer.
Wilkening S; Tavelin B; Canzian F; Enquist K; Palmqvist R; Altieri A; Hallmans G; Hemminki K; Lenner P; Försti A
Carcinogenesis; 2008 Jun; 29(6):1202-6. PubMed ID: 18448485
[TBL] [Abstract][Full Text] [Related]
34. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
35. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
37. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
[TBL] [Abstract][Full Text] [Related]
38. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer.
Langenskiöld M; Holmdahl L; Angenete E; Falk P; Nordgren S; Ivarsson ML
Tumour Biol; 2009; 30(4):210-20. PubMed ID: 19776673
[TBL] [Abstract][Full Text] [Related]
39. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
40. Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer.
Shih CM; Kuo WH; Lin CW; Chen W; Cheng WE; Chen SC; Lee YL
Clin Chim Acta; 2011 Jan; 412(1-2):194-8. PubMed ID: 20937265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
